Taken together, these results suggest a broad correlation between the magnitude of immune cell expansion and the development of treatment-associated toxicities, with low-dose IL-2/mAb or IL-23XFc treatments displaying higher levels of toxicity, particularly pulmonary oedema, compared to IL-2WTFc. Here, IL2 is linked to pulmonary edema.